TrialBMC infectious diseases2013

Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results.

Princy Kumar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.